Italia markets close in 5 hours 50 minutes

Cingulate Inc. (CING)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
0,9700+0,0092 (+0,96%)
Alla chiusura: 04:00PM EST
0,9508 -0,02 (-1,98%)
Dopo ore: 07:40PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente0,9608
Aperto1,0000
Denaro0,0000 x 1000
Lettera0,0000 x 1000
Min-Max giorno0,9503 - 1,0000
Intervallo di 52 settimane0,6640 - 2,2000
Volume9.698
Media Volume52.916
Capitalizzazione10,97M
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-2,1560
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A5,00
  • GlobeNewswire

    Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD

    Trial Results Expected 1H 2023 Company to Host Investor and Business Development Meetings Adjacent to Upcoming J.P. Morgan Healthcare Conference in San Francisco KANSAS CITY, Kan., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the initiation of the first Phase 3 clinic

  • GlobeNewswire

    Cingulate Benzinga All Live Access Appearance Rescheduled for December 16

    KANSAS CITY, Kan., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on Friday December 16, 2022, at 9:20 a.m. CST. The appearance had previously been scheduled for Friday

  • GlobeNewswire

    Cingulate to Participate in Benzinga All Live Access Event

    KANSAS CITY, Kan., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on Friday December 2, 2022, at 10 a.m. CST. The discussion will address the current unmet needs in Attention De